$0.78
-0.02 (-2.32%)
Open$0.77
Previous Close$0.80
Day High$0.87
Day Low$0.75
52W High$2.84
52W Low$0.55
Volume—
Avg Volume20.12M
Market Cap191.07M
P/E Ratio—
EPS$-0.57
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,850.3% upside
Current
$0.78
$0.78
Target
$15.22
$15.22
$10.64
$15.22 avg
$24.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.60M | 3.06M | 180.17M |
| Net Income | -71,987,652 | -55,195,848 | 5.71M |
| Profit Margin | -2,003.6% | -1,903.4% | 3.2% |
| EBITDA | -216,938,776 | -175,576,620 | 9.37M |
| Free Cash Flow | — | — | 5.00M |
| Rev Growth | +17.4% | +17.4% | +21.8% |
| Debt/Equity | 20.86 | 20.86 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |